Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline

In this study, we aimed to evaluate the efficacy of pentoxifylline and atorvastatin in the treatment of non-alcoholic fatty liver disease (NAFLD). The study included 98 patients with histologically confirmed NAFLD divided into 2 groups as follows: group I (57 dyslipidemic patients, receiving atorvas...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-05, Vol.13 (5), p.2375-2381
Main Authors: Cioboată, Ramona, Găman, Alice, Traşcă, Diana, Ungureanu, Anca, Docea, Anca Oana, Tomescu, Paul, Gherghina, Florin, Arsene, Andreea Letitia, Badiu, Corin, Tsatsakis, Aristides M, Spandidos, Demetrios A, Drakoulis, Nikolaos, Călina, Daniela
Format: Article
Language:English
Subjects:
Alcohol
Atorvastatin
Biopsy
Body mass index
Cholesterol
Comparative analysis
Consent
Diabetes
Dosage and administration
Drug therapy
Family medical history
Hepatitis
Insulin resistance
Liver diseases
Metabolic syndrome
Obesity
Patient outcomes
Pentoxifylline
Phosphatase
Polycystic ovary syndrome
Standard deviation
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we aimed to evaluate the efficacy of pentoxifylline and atorvastatin in the treatment of non-alcoholic fatty liver disease (NAFLD). The study included 98 patients with histologically confirmed NAFLD divided into 2 groups as follows: group I (57 dyslipidemic patients, receiving atorvastatin 20 mg/day and group II (41 non-dyslipidemic patients, treated with pentoxifylline, 800 mg/day). The present study was conducted for a mean of 32.8±3.4 weeks. For all patients, we determined the body mass index, a liver biopsy was performed, and we measured the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), total cholesterol (TC) and triglycerides (TG) at the beginning and at the end of the study period. The NAFLD activity score (NAS) was used to evaluate the liver biopsies for steatosis, fibrosis and necroinflammation. The patients in group I exhibited a considerable reduction in ALT, AST, GGT, TC, AP and TG levels (P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.4256